独家 | 绿谷深陷经营困境，停产阿尔茨海默病药物

Core Points - The company, Green Valley Pharmaceutical Technology, is facing severe operational difficulties and extreme cash flow constraints [4][5] - The product, Gannuo Sodium Capsules, has reached a critical turning point in its product lifecycle, leading to the suspension of its production and related operations [2][5] - The drug, which is intended for the treatment of mild to moderate Alzheimer's disease, has been controversial due to questions surrounding its efficacy and clinical trial processes [2][4] Company Summary - Green Valley has halted the production of Gannuo Sodium Capsules and is closing relevant office and production areas [2] - The drug received conditional approval from the National Medical Products Administration in November 2019, with specific requirements for further studies and safety evaluations [2] - The company announced the suspension of international Phase III clinical trials in May 2022, citing factors such as the pandemic and funding issues [2] Industry Context - Alzheimer's disease presents a significant challenge for the medical community, with a complex pathogenesis and a long disease course, impacting many patients globally, particularly in an aging Chinese society [4] - Major pharmaceutical companies have invested hundreds of billions of dollars in the development of Alzheimer's treatments, with very few new drugs approved in the last two decades, primarily focusing on symptom management [4]